Lipid‐lowering efficacy and safety of alirocumab in patients with or without diabetes: <scp>A</scp> sub‐analysis of <scp>ODYSSEY COMBO II</scp>

Lawrence A. Leiter, Yehuda Handelsman, Christopher P. Cannon et al.|Diabetes Obesity and Metabolism|2017

Cited by 50